In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine
about
Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir ResistanceMechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosineAlkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistanceThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptaseThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidineChanging patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsA novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Bioinformatics approach to predicting HIV drug resistance.Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceSimultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assayComparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variantsMolecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Scaleable processes for the synthesis of (-)-β-D-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-β-D-2-aminopurine dioxolane (APD).A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue.
P2860
Q27657718-C8BFDCC7-2AE3-41BC-85A4-45170B213380Q28345240-B49764DC-A0CD-415F-AF64-F9F5D93D6B12Q28365182-E262C102-5A0D-43B5-A29D-89790ED79150Q33681279-6D91E764-2C4F-4838-AED0-5D58654B342DQ33857855-CBFC0830-3383-4220-8D7A-6A089E1E2B48Q33889635-C2395F6B-C217-409A-9F7E-119708ECB823Q33935229-D24B0DC8-AB64-4D59-9453-776CCFA47BEDQ34414078-D6C89E11-543F-41DF-AF00-1C8197785C01Q34465037-3ABD99E9-FCCE-45FE-841B-629867E32642Q34573897-7C9B0D94-4EDE-4876-A49E-60DBA75F3750Q34647936-FD8E39A1-CF40-4A7C-963E-D1A1DD181C10Q34976902-A774EA3B-4044-409D-B8B4-93B89A8AB9F8Q35043368-351FD844-C2ED-487A-B2C8-A98BD27BC2C4Q35636514-D3EB4F11-49CC-4FBC-93E7-A6BE17381D9AQ36069767-3D6A9ABD-58FB-4AF4-810E-31CE3A3C7DD4Q36094751-C53BD1BE-451E-4B8C-BC4F-AF2097111194Q36276790-594A82A3-E59D-4BB7-AA3C-453A183F85CAQ36411681-23275D66-F0F4-4A51-846A-767EE8D035D6Q36964321-C99354C7-7471-4CA2-BF25-D12B5F7BDDD7Q36993425-1276647E-F81A-4FB8-B2B4-531D415BEDBFQ37288671-91031724-FEA8-42EA-9C74-959A33822731Q37404670-916A68D0-591D-46B8-AA1B-8F0578EAC072Q37404676-5142ABD0-39C5-4A39-B3EE-1AA2BB1348FEQ37489188-A14054D1-AFCC-4DF5-B260-AED64E5D77E8Q38351813-303944AC-F5D2-49D9-B773-26E70228F4E1Q39651722-0E58CD16-71AD-4C7B-ABD9-6EB30EC92565Q39657878-652EA03D-6FA2-4BAD-8707-2EFF8633A234Q39730794-2A3FFB02-95B9-47A3-9A0B-03D9D550B7D4Q40291210-58E12419-2616-47EC-BA49-3EBB03DBD7C1Q40454877-E72E3CA2-647E-47C3-9890-2942E00E4FB7Q40642031-0C585A61-8964-4567-B6E2-1C7D70320522Q40706086-1028334A-2D0A-448D-B855-763FB2963827Q41206224-ED6C8425-C7DD-4EE2-8395-DB9A9FF005E5Q41862836-EE729598-CCE2-446E-810C-9E41E34A8B5FQ41879018-623C3A8B-8EF0-4AE4-BFB7-D78FDD68DF72Q42120771-A9BB2F5D-2440-44B6-A7B4-4016571B27FCQ43077557-03E1BF1F-3553-4258-9FD2-49C6548EDABDQ44372189-A26BA154-184F-41FE-9757-740C12B6AAF8Q44741225-EC15E47C-37A9-4690-B243-0B997FD19541Q44916253-BADD19CD-043D-43CA-9135-DA0394E59790
P2860
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@ast
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@en
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@nl
type
label
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@ast
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@en
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@nl
prefLabel
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@ast
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@en
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@nl
P2093
P2860
P1476
In vitro selection of mutation ...... to 3'-azido-3'-deoxythymidine
@en
P2093
J L Hammond
J W Mellors
R F Schinazi
S C Cavalcanti
P2860
P304
P356
10.1128/AAC.44.7.1783-1788.2000
P407
P577
2000-07-01T00:00:00Z